Raymond James appointed Dane Leone as a managing director responsible for biotechnology coverage in the firm’s equity research department.
He joins the firm’s existing equity research analysts focused on the biotechnology sector: Reni Benjamin, Laura Chico and Steve Seedhouse, as well as Elliot Wilbur, who covers specialty pharmaceuticals.
Mr. Leone joins Raymond James from BTIG, where he spent four years covering biotechnology stocks, having previously covered medical technology. Prior to BTIG, he spent more than four years as a healthcare services analyst at Macquarie.
In a statement, Brian Alexander, director of equity research, said Mr. Leone’s reputation for analytical rigor, comprehensive research and objective investment advice makes him an ideal candidate to grow Raymond’s life sciences franchise.
“With Dane’s addition, we look forward to meaningful coverage expansion of middle-market growth companies in key therapeutic areas,” he added.